PBLS Company Profile and Key Details

Parabilis Medicines, Inc. (NASDAQ:PBLS) closed at $32.81 USD, gaining $2.00 (6.49%) from the previous close of $30.81. The stock is currently within 5% of its 52-week high $24.51 and $34.47. With a market capitalization of about $107.45 million, Parabilis Medicines, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 942.64 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Parabilis Medicines, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mathai Mammen, the company employs approximately 145 people and listed since June 10, 2026. Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company.

Average 10-day trading volume of 490.37 thousand shares is below the 3-month average of 737.62 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $40.00. The high target offers 46.06% upside. The low target suggests 29.83% downside. The mean target is $41.67. This offers 35.25% upside.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that Parabilis Medicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.9%, with price expected at $29.30 by August 05, 2026, within a range of $28.15 to $30.23 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by October 20, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected gain of 551.48%, with price at $200.72 by July 22, 2027, within a range of $200.49 to $200.95.

Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $41.67, suggesting 35.25% upside. Our AI forecast model points to short-term weakness (-4.9% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (551.48% over one year), with expected trading ranges indicating moderate volatility.